1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006.
2. Мукоактивная терапия. Под ред. А.Г.Чучалина, А.С.Белевского. М.: Атмосфера, 2006; 2-4.
3. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance. Eur Respir J 1999; 13: 1177–88.
4. Moretti V, Lopez-Vidriero MT, Pavia D, Clarke SW. Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis. Thorax 1997; 52: 176–80.
5. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004; 59 (11): 992–6.
6. Машковский М.Д. Лекарственные средства: Пособие для врачей. Харьков: Торсинг, 1997; 2: 112–4.
7. Рациональная фармакотерапия заболеваний органов дыхания: Руководство для практикующих врачей. Под ред. А.Г.Чучалина. М.: Литтерра, 2004.
8. Laube B, Auchi R, Shields D et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (2): 752–60.
9. Rosenstein BJ, Johnson CAC. Long-term follow-up of Phase III rhDNase trial. Pediatric Pulmonology 1994; Suppl. 10: 113–4. 
10. Rogers DF. Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respiratory Care 2007; 52 (9).
11. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50: 31–42.
12. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294–8.
13. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
14. De Flora S, Grass C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535.
15. Lemy-Debois N et al. Oral acetylcysteine in bronchopulmonary disease. Comparative clinical trial with bromhexine. Acta Ther 1978; 4: 125–32.
16. Nowak D, Antczak A, Krol M et al. Antioxidant properties of ambroxol. Free Radic Biol Med 1994; 16: 517–22.
17. Olivieri D, Zavattini G, Nomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long term multicenter trial. Respiration 1987; 51 (Suppl. 1): 42–51.
18. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol in antioxidant therapy. Respir Med 2002; 41 (12): 1175–8.
19. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in antioxidant therapy. Respir Med 1998; 92: 609–23.
20. Carpagnano GE, Resta O et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monogydrate (SCMC-Lys). Eur J Pharmacol 2004; 505 (1–3): 169–75.
21. Bolser DC. Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2006; 129: 238S–249S.
22. Yasuda H, Yamaya M, Sasaki T et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J 2006; 28: 51–8.
23. Donaldson SH, Bennett WD et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354 (3): 229–40.
24. Guo R, Pittler MH et al. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006; 28: 330–8.

Н.Н.Мещерякова, С.Ю.Чикина